Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies | Latest News RSS feed

Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies - Latest News


Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

Eli Lilly and Company LLY along with Boehringer Ingelheim announced positive top-line data from two clinical studies – EASE 2 and EASE 3 – from the phase III EASE program evaluating SGLT2 inhibitor, J... read more

Sanofi to discontinue phase III studies of iniparib & otamixaban as drugs fail to meet endpoints

The randomized phase III ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC) did not meet its primary endpoint. In the study ... seven growth platforms: diabetes solutions, hum... read more

2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025

HbA1c measures blood glucose over 90 days, and is the primary endpoint of virtually all pivotal trials ... so Eli Lilly has much to celebrate going into the next decade. An added plus is that Lilly ha... read more

Looking for another news?


Sanofi says LixiLan Diabetes Drug Trials Meet Targets

France’s Sanofi said on Sunday that two late-stage Phase III ... a drug developed with Danish drugmaker Zealand Pharma , and Sanofi’s Lantus. It targets patients suffering from type 2 diabetes. “Both ... read more


EMA reviews Lilly/BI diabetes drug 'similar' to Lantus

The investigational long-acting insulin is similar to Lantus (insulin glargine), Sanofi's biggest-selling drug; in the first-quarter, its sales leapt 19.7% to 1.34 billion euros. Lilly ... Phase III s... read more

Lilly delays filing of Lantus rival on safety concerns

Lilly has said it needs to explore whether "changes in liver" fat seen in phase III trials ... the drug for approval," commented Enrique Conterno, president of Lilly Diabetes. "Our priority is deliver... read more

Study shows AZ’s Farxiga diabetes drug cuts heart risks

AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial. Boehringer Ingelheim and Eli Lilly’s Jardiance ... in the LEADER study. ... read more

Alzheimer's disease continues to RAGE as Vtv falls victim in phase III effort

The company completed phase I studies in healthy volunteers and 10-week and 18-month phase II studies in patients with mild to moderate AD to support the phase III registration ... would be for the tr... read more

Uncertainty At Johnson & Johnson Creates Risk

Johnson & Johnson recently discontinued phase iii trials for the Alzheimer drug, Bapineuzumab IV as it failed to meet the co-primary endpoints ... a SGLT2 inhibitor to treat diabetes, but Eli Lilly (N... read more

Sanofi says LixiLan diabetes drug trials meet targets

PARIS (Reuters) - France’s Sanofi said on Sunday that two late-stage Phase III ... drug developed with Danish drugmaker Zealand Pharma, and Sanofi’s Lantus. It targets patients suffering from type 2 d... read more

Lilly's Alzheimer Drug Fails Phase III Study, Stock Down

Lilly ... in late-stage trials. Top-line data on solanezumab from two phase III EXPEDITION studies conducted on patients with mild-to-moderate Alzheimer's disease were announced back in Aug 2012. Sola... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us